About
multiQure (formerly Pure Biologics) develops RNAi gene therapies targeting rare genetic neurodegenerative disorders, primarily Huntington's disease, aiming to halt disease progression rather than just alleviate symptoms. The company also pursues immuno-oncology projects.
Explore multiQure's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.